COVID -19 Management of adult patients with suspected COVID -19 |
| Publication: 09/04/2020 |
| Next review: 19/05/2022 |
| Clinical Guideline |
| CURRENT |
| ID: 6341 |
| Approved By: Clinical Advisory Group |
| Copyright© Leeds Teaching Hospitals NHS Trust 2022 |
This Clinical Guideline is intended for use by healthcare professionals within Leeds unless otherwise stated. |
Management of adult patients with suspected COVID-19
- Management of adult patients with suspected COVID-19
- Management of adult patients with suspected COVID-19
- Barcitinib for patients over 2 years hospitalised with acute with COVID-19
- Remdesivir adult prescribing criteria for Hospital-Onset COVID-19 & NHS England request form
- Remdesivir adult prescribing criteria & NHS England request form
- Paxlovid (PF-07321332/nirmatrelvir plus ritonavir) for adult patients with hospital-onset with COVID-19
- Sarilumab - NHSE BlueTeq request form for adult level 2 care patients (when tocilizumab unavailable)
- Sotrovimab for adult patients with hospital-onset with COVID-19
- Tocilizumab - NHSE BlueTeq request form for adult level 2 care patients
- ISARIC 4C Mortality Score
| |
Provenance
| Record: | 6341 |
| Objective: | |
| Clinical condition: | Suspected COVID-19 |
| Target patient group: | Adults |
| Target professional group(s): | Pharmacists Secondary Care Doctors Secondary Care Nurses |
| Adapted from: |
Evidence base
Not supplied
Approved By
Clinical Advisory Group
Document history
LHP version 16.0
Related information
Not supplied
Equity and Diversity
The Leeds Teaching Hospitals NHS Trust is committed to ensuring that the way that we provide services and the way we recruit and treat staff reflects individual needs, promotes equality and does not discriminate unfairly against any particular individual or group.